End Price Gouging for Medications Act

The End Price Gouging for Medications Act establishes annual reference prices for prescription drugs, set based on the lowest international prices from designated countries (like Germany and Canada) or factors like drug value and research costs. These reference prices cap drug costs in federal health programs (including Medicare, Medicaid, VA care, and TRICARE) and require manufacturers to sell all covered drugs at or below this price to every patient, including those without insurance or in private plans. Manufacturers violating this rule face civil penalties of five times the excess revenue collected, with funds redirected to National Institutes of Health drug research. The bill directly affects drug manufacturers and ensures lower costs for patients across all health coverage types.